https://www.selleckchem.com/pr....oducts/2-2-2-tribrom
BACKGROUND Despite advances in targeted kinase inhibitor development for patients with medullary thyroid cancer (MTC), most patients develop resistance and would benefit from alternative approaches. Immune-based therapies are now considered for patients with progressive MTC. This study is the first comprehensive assessment of the immune milieu, immune suppressive molecules, and potential tumor antigens in patients with MTC. METHODS Primary and/or regionally metastatic tumor tissues from 46 patients with MTC were screened f
Like
Comment
Share
